These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27564385)

  • 1. Cost-Effectiveness Analysis of Anticholinergics Versus Botox for Urgency Urinary Incontinence: Results From the Anticholinergic Versus Botox Comparison Randomized Trial.
    Visco AG; Zyczynski H; Brubaker L; Nygaard I; Xu X; Lukacz ES; Paraiso MF; Greer J; Rahn DD; Meikle SF; Honeycutt AA
    Female Pelvic Med Reconstr Surg; 2016; 22(5):311-6. PubMed ID: 27564385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to Oral Therapy for Urgency Urinary Incontinence: Results from the Anticholinergic Versus Botox Comparison (ABC) Trial.
    Visco AG; Brubaker L; Jelovsek JE; Wilson TS; Norton P; Zyczynski HM; Spino C; Sirls L; Nguyen JN; Rahn DD; Meikle SF; Nolen TL;
    Female Pelvic Med Reconstr Surg; 2016; 22(1):24-8. PubMed ID: 26516810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder.
    Shepherd JP; Carter-Brooks CM; Chermanksy C
    Int Urogynecol J; 2018 Aug; 29(8):1213-1219. PubMed ID: 29671033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
    Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
    J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry.
    Nilsson FO; Linnér L; Samuelsson E; Milsom I
    BJU Int; 2012 Jul; 110(2):240-6. PubMed ID: 22093912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective.
    Hamid R; Loveman C; Millen J; Globe D; Corbell C; Colayco D; Stanisic S; Gultyaev D
    Pharmacoeconomics; 2015 Apr; 33(4):381-93. PubMed ID: 25526842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Cost-Effectiveness Analysis of Anticholinergics versus Botox for Urgency Urinary Incontinence: Results from the Anticholinergic versus Botox Comparison Randomized Trial.
    Wein AJ
    J Urol; 2017 Sep; 198(3):487-492. PubMed ID: 28817919
    [No Abstract]   [Full Text] [Related]  

  • 8. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
    Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial.
    Visco AG; Brubaker L; Richter HE; Nygaard I; Paraiso MF; Menefee SA; Schaffer J; Wei J; Chai T; Janz N; Spino C; Meikle S;
    Contemp Clin Trials; 2012 Jan; 33(1):184-96. PubMed ID: 22008247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.
    Visco AG; Brubaker L; Richter HE; Nygaard I; Paraiso MF; Menefee SA; Schaffer J; Lowder J; Khandwala S; Sirls L; Spino C; Nolen TL; Wallace D; Meikle SF;
    N Engl J Med; 2012 Nov; 367(19):1803-13. PubMed ID: 23036134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.
    Harvie HS; Amundsen CL; Neuwahl SJ; Honeycutt AA; Lukacz ES; Sung VW; Rogers RG; Ellington D; Ferrando CA; Chermansky CJ; Mazloomdoost D; Thomas S
    J Urol; 2020 May; 203(5):969-977. PubMed ID: 31738113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial.
    Amundsen CL; Richter HE; Menefee S; Vasavada S; Rahn DD; Kenton K; Harvie HS; Wallace D; Meikle S
    Contemp Clin Trials; 2014 Mar; 37(2):272-83. PubMed ID: 24486637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.
    Freemantle N; Khalaf K; Loveman C; Stanisic S; Gultyaev D; Lister J; Drake M
    Eur J Health Econ; 2016 Sep; 17(7):911-21. PubMed ID: 26482712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does symptom severity predict response to low-dose onabotulinumtoxinA for the treatment of urgency urinary incontinence?
    Gonzalez HM; Wheat JE; Dengler KL; Barbier HM; Gehrich AP; Gruber DD; Warner WB
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():118-124. PubMed ID: 33212321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 100 U With 200 U of Intradetrusor OnabotulinumToxinA for Nonneurogenic Urgency Incontinence.
    Hendrickson WK; Amundsen CL; Rahn DD; Meyer I; Bradley MS; Smith AL; Myers DL; Jelovsek JE; Lukacz ES
    Female Pelvic Med Reconstr Surg; 2021 Mar; 27(3):140-146. PubMed ID: 33620895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can botox improve night-time overactive bladder symptoms in women?
    Miotla P; Cartwright R; Futyma K; Bogusiewicz M; Skorupska K; Winkler I; Rechberger T
    Neurourol Urodyn; 2017 Mar; 36(3):648-652. PubMed ID: 26915654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway.
    Hansson-Hedblom A; Axelsson I; Jacobson L; Tedroff J; Borgström F
    J Headache Pain; 2020 Aug; 21(1):99. PubMed ID: 32787820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mobile app for the treatment of female mixed and urgency incontinence: a cost-effectiveness analysis in Sweden.
    Ekersund J; Samuelsson E; Lindholm L; Sjöström M
    Int Urogynecol J; 2022 May; 33(5):1273-1282. PubMed ID: 35278093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Women's perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment.
    Balchandra P; Rogerson L
    Int Urogynecol J; 2014 Aug; 25(8):1059-64. PubMed ID: 24633067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.